Wednesday, April 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

OSHA publishes long-awaited emergency temporary standard on workplace COVID-19 vaccination

The U.S. Occupational Safety and Health Administration (OSHA) released its long-anticipated emergency temporary standard (ETS) governing vaccination in the workplace. OSHA published both a summary of the ETS and a fact sheet. This alert covers the nuts and bolts of the ETS. In the coming days we look forward to publishing further analysis of the ETS and the potential and anticipated challenges it faces.

The bottom-line takeaway from the ETS is that all covered employers will need to require their employees to either be fully vaccinated for COVID-19 or submit to weekly testing. The first compliance deadline is December 5, 2021. Weekly testing requirements for employees who are not vaccinated must be met by January 4, 2022.

Source: Sidley Law Offices

https://www.sidley.com/en/insights/newsupdates/2021/11/osha-publishes-long-awaited-emergency-temporary-standard-on-workplace-covid-vaccination

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!